Exploratory analysis of CT-derived radiomic features and adipose tissue distribution in relation to lipid metabolism pathway activity in ovarian serous cystadenocarcinoma
Introduction: Ovarian cancer is characterized by high recurrence rates and complex metabolic reprogramming. Lipid metabolism pathways may influence tumor imaging phenotypes and contribute to biologic heterogeneity.
Objective: This study investigated whether computed tomography (CT)-derived radiomic features are associated with metabolic activity profiles in ovarian cancer.
Methods: This retrospective radiogenomic study included 68 patients from the Cancer Genome Atlas Ovarian Cancer cohort with available contrast-enhanced CT imaging and matched transcriptomic data. Patients were stratified into high and low metabolic activity groups according to lipid metabolism-related pathway expression profiles. A two-dimensional radiomic approach was adopted using the axial CT slice showing the largest tumor area. Tumor regions were manually segmented, and handcrafted radiomic features were extracted using a custom pipeline developed in Python. Statistical comparisons between groups were performed using the Mann–Whitney U test with Benjamini–Hochberg false discovery rate (FDR) correction.
Results: Several radiomic features showed nominal or borderline differences between high- and low-metabolic-activity groups, including glcm_ASM_std (p = 0.027), shape_perimeter_mm (p = 0.045), glrlm_rln (p = 0.049), shape_minor_axis_length_px (p = 0.050), and intensity_p10_HU (p = 0.053). Tumors with higher metabolic activity tended to exhibit larger morphologic dimensions and subtle texture alterations. Subcutaneous adipose tissue (SAT) demonstrated the strongest inverse correlation with LipidScore (Spearman rho = −0.24), and a non-significant trend toward higher SAT values was observed in the low-lipid-metabolism group (p = 0.072). However, none of the radiomic features remained statistically significant after FDR correction.
Conclusion: CT-derived radiomic features showed weak exploratory associations with metabolic activity-related molecular profiles in ovarian cancer. Although no robust associations were confirmed after multiple-comparison correction, the observed trends suggest potential radiogenomic interactions related to tumor metabolism that warrant further investigation in larger cohorts.
- Ji Z, Shen Y, Feng X, et al. Deregulation of lipid metabolism: the critical factors in ovarian cancer. Front Oncol. 2020;10:593017. doi: 10.3389/fonc.2020.593017
- Chaudhry S, Thomas SN, Simmons GE Jr. Targeting lipid metabolism in the treatment of ovarian cancer. Oncotarget. 2022;13(1):768-783. doi: 10.18632/oncotarget.28241
- Jiang L, Fang X, Wang H, Li D, Wang X. Ovarian cancer-intrinsic fatty acid synthase prevents anti-tumor immunity by disrupting tumor-infiltrating dendritic cells. Front Immunol. 2018;9:2927. doi: 10.3389/fimmu.2018.02927
- Li J, Condello S, Thomes-Pepin J, et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell. 2017;20(3):303-314.e5. doi: 10.1016/j.stem.2016.11.004
- Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5(1):e189. doi: 10.1038/oncsis.2015.49
- Zhao S, Cheng L, Shi Y, Li J, Yun Q, Yang H. MIEF2 reprograms lipid metabolism to drive progression of ovarian cancer through ROS/AKT/mTOR signaling pathway. Cell Death Dis. 2021;12(1):18. doi: 10.1038/s41419-020-03336-6
- Zhang Q, Zhou W, Yu S, et al. Metabolic reprogramming of ovarian cancer involves ACSL1-mediated metastasis stimulation through upregulated protein myristoylation. Oncogene. 2021;40(1):97-111. doi: 10.1038/s41388-020-01516-4
- Ma Y, Temkin SM, Hawkridge AM, et al. Fatty acid oxidation: an emerging facet of metabolic transformation in cancer. Cancer Lett. 2018;435:92-100. doi: 10.1016/j.canlet.2018.08.006
- Meier A, Veeraraghavan H, Nougaret S, et al. Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer. Abdom Radiol (NY). 2019;44(6):2040-2047. doi: 10.1007/s00261-018-1840-5
- Vargas HA, Veeraraghavan H, Micco M, et al. A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. Eur Radiol. 2017;27(9):3991-4001. doi: 10.1007/s00330-017-4779-y
- Jian J, Li Y, Pickhardt PJ, et al. MR image-based radiomics to differentiate type I and type II epithelial ovarian cancers. Eur Radiol. 2021;31(1):403-410. doi: 10.1007/s00330-020-07091-2
- Li H, Cai S, Deng L, et al. Prediction of platinum resistance for advanced high-grade serous ovarian carcinoma using MRI-based radiomics nomogram. Eur Radiol. 2023;33(8):5298-5308. doi: 10.1007/s00330-023-09552-w
- Holback C, Jarosz R, Prior F, et al. The Cancer Genome Atlas Ovarian Cancer Collection (TCGA-OV). Published online 2016. doi: 10.7937/K9/TCIA.2016.NDO1MDFQ
- Noumura Y, Kamishima T, Sutherland K, Nishimura H. Visceral adipose tissue area measurement at a single level: can it represent visceral adipose tissue volume? Br J Radiol. 2017;90(1077):20170253. doi: 10.1259/bjr.20170253
- Greco F, Panunzio A, Bernetti C, Tafuri A, Beomonte Zobel B, Mallio CA. Exploring the ADAM12 expression in clear cell renal cell carcinoma: a radiogenomic analysis on CT imaging. Acad Radiol. 2024;31(9):3672-3677. doi: 10.1016/j.acra.2024.02.032
- Liu Z, Duan T, Zhang Y, et al. Radiogenomics: a key component of precision cancer medicine. Br J Cancer. 2023;129(5):741-753.
- Song L, Zhu Z, Mao L, et al. Clinical, conventional CT and radiomic feature-based machine learning models for predicting ALK rearrangement status in lung adenocarcinoma patients. Front Oncol. 2020;10:369. doi: 10.3389/fonc.2020.00369
- Peeken JC, Bernhofer M, Wiestler B, et al. Radiomics in radiooncology—challenging the medical physicist. Phys Med. 2018;48:27-36. doi: 10.1016/j.ejmp.2018.03.012
- Zeng S, Wang XL, Yang H. Radiomics and radiogenomics: extracting more information from medical images for the diagnosis and prognostic prediction of ovarian cancer. Mil Med Res. 2024;11(1). doi: 10.1186/s40779-024-00580-1
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi: 10.1016/j.cell.2011.02.013
- Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev. 2019;99(4):1819-1875. doi: 10.1152/physrev.00035.2018
- Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669-680. doi: 10.1038/s41568-021-00378-6
- Corn KC, Windham MA, Rafat M. Lipids in the tumor microenvironment: from cancer progression to treatment. Prog Lipid Res. 2020;80:101055. doi: 10.1016/j.plipres.2020.101055
- Calder PC. Functional roles of fatty acids and their effects on human health. JPEN J Parenter Enteral Nutr. 2015;39(1 suppl):18S-32S. doi: 10.1177/0148607115595980
- Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019;92:121-135. doi: 10.1016/j.metabol.2018.11.001
- Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: local and systemic mechanisms. Annu Rev Med. 2015;66(1):297-309. doi: 10.1146/annurev-med-050913-022228
- Brown KA, Scherer PE. Update on adipose tissue and cancer. Endocr Rev. 2023;44(6):961-974. doi: 10.1210/endrev/bnad015
- Vona-Davis L, Rose DP. The obesity-inflammation-eicosanoid axis in breast cancer. J Mammary Gland Biol Neoplasia. 2013;18(3-4):291-307. doi: 10.1007/s10911-013-9299-z
- Kolb H. Obese visceral fat tissue inflammation: from protective to detrimental? BMC Med. 2022;20(1):494. doi: 10.1186/s12916-022-02672-y
- Sah S, Bifarin OO, Moore SG, et al. Serum lipidome profiling reveals a distinct signature of ovarian cancer in Korean women. Cancer Epidemiol Biomarkers Prev. 2024;33(5):681-693. doi: 10.1158/1055-9965.EPI-23-1293
- Li Y, Shang C, Liang H, Zhang K, Wu Y, Guo H. Associations of novel serum lipid index with epithelial ovarian cancer chemoresistance and prognosis. Front Oncol. 2023;13:1052760. doi: 10.3389/fonc.2023.1052760
- Zhong X, Bilal M, Zhou Y, et al. Elucidating the role of fatty acid reprogramming in ovarian cancer: insights cross-talk between blood, subcutaneous fat, and ovarian cancer tissues. Front Oncol. 2025;15:1530487. doi: 10.3389/fonc.2025.1530487
- Matuszczak M, Kiljańczyk A, Marciniak W, et al. Blood molybdenum level as a marker of cancer risk on BRCA1 carriers. Hered Cancer Clin Pract. 2024;22(1). doi: 10.1186/s13053-024-00291-7
- Wen Z, Liu H, Li M, et al. Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration. Oncogene. 2015;34(10):1241-1252. doi: 10.1038/onc.2014.85
- Rocconi RP, Kirby TO, Seitz RS, et al. Lipoxygenase pathway receptor expression in ovarian cancer. Reprod Sci. 2008;15(3):321-326. doi: 10.1177/1933719108316390
- Ghosh N, Chaki R, Mandal V, Mandal SC. COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 2010;62(2):233-244. doi: 10.1016/S1734-1140(10)70262-0
- Gu P, Su Y, Guo S, et al. Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. Cancer Invest. 2008;26(8):822-829. doi: 10.1080/07357900801941860
- Wang YP, Wang QY, Li CH, Li XW. COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. Chem Biol Interact. 2018;292:24-29. doi: 10.1016/j.cbi.2018.06.020
- Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25(5-6):495-520. doi: 10.1016/j.mam.2004.06.004
- Shao H, Mohamed EM, Xu GG, et al. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. Oncotarget. 2016;7(4):3832-3846. doi: 10.18632/oncotarget.6757
